Last reviewed · How we verify
Marketed rabies vaccine
This vaccine stimulates the immune system to produce antibodies and cellular immunity against the rabies virus, preventing infection after exposure.
This vaccine stimulates the immune system to produce antibodies and cellular immunity against the rabies virus, preventing infection after exposure. Used for Rabies post-exposure prophylaxis (PEP) in individuals exposed to potentially rabid animals, Rabies pre-exposure prophylaxis (PrEP) in high-risk populations (veterinarians, laboratory workers, travelers to endemic regions).
At a glance
| Generic name | Marketed rabies vaccine |
|---|---|
| Sponsor | Sinovac Biotech Co., Ltd |
| Drug class | Inactivated viral vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Rabies vaccines work by introducing inactivated or attenuated rabies virus antigen to trigger both humoral (antibody) and cell-mediated immune responses. This priming allows the vaccinated individual's immune system to rapidly recognize and neutralize rabies virus if exposed, preventing the virus from reaching the central nervous system where it causes fatal encephalitis.
Approved indications
- Rabies post-exposure prophylaxis (PEP) in individuals exposed to potentially rabid animals
- Rabies pre-exposure prophylaxis (PrEP) in high-risk populations (veterinarians, laboratory workers, travelers to endemic regions)
Common side effects
- Injection site pain, erythema, or swelling
- Headache
- Myalgia or fatigue
- Fever
- Nausea
Key clinical trials
- Immunogenicity and Safety Assessment of Rabies Vaccine (Vero Cell) for Human Use, Freeze-dried (PHASE3)
- Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis Regimen (PHASE3)
- Immunogenicity and Safety of Different Dosages of Rabies Vaccine (Serum-free Vero Cell) (PHASE2)
- Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Pre-exposure Prophylaxis Regimen (PHASE3)
- Inactivated Influenza Vaccine Effectiveness in Tropical Africa (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Marketed rabies vaccine CI brief — competitive landscape report
- Marketed rabies vaccine updates RSS · CI watch RSS
- Sinovac Biotech Co., Ltd portfolio CI